VNDA · Vanda Pharmaceuticals Inc. · Documents

Nov 6

Earnings call

Q3 2024 earnings call

Nov 6

Current report 8-K

Financial results

Oct 15

Current report 8-K Events of Oct 14

Other events

Oct 3

Current report 8-K Events of Oct 2

Charter or bylaw amendment, or fiscal year change

Sep 19

Current report 8-K

Other events

Aug 8

Current report 8-K Events of Aug 7

Entered into a material agreement, Change to shareholders' rights

Aug 1

Quarterly report 10-Q FY2024 Q2, ended Jun 30

Quarterly report for FY2024 Q2

Revenue $50.47M ▲ 9.6% Net loss $4.52M Diluted EPS -$0.08

Jul 31

Earnings call

Q2 2024 earnings call

Jul 31

Current report 8-K

Financial results

Jun 20

Current report 8-K Events of Jun 19

Other events

Jun 13

Current report 8-K

Other events

Jun 6

Current report 8-K

Regulation FD disclosure

May 24

Current report 8-K/A Events of May 17

Shareholder vote results

May 24

Current report 8-K

Other events

May 20

Current report 8-K Events of May 17

Shareholder vote results

May 13

Proxy statement DEFA14A

Proxy statement

May 9

Quarterly report 10-Q FY2024 Q1, ended Mar 31

Quarterly report for FY2024 Q1

Revenue $47.46M ▼ 24.1% Net loss $4.15M Diluted EPS -$0.07

May 9

Proxy statement DEFA14A

Proxy statement

May 8

Earnings call

Q1 2024 earnings call

May 8

Current report 8-K

Financial results

May 7

Current report 8-K

Other events

May 3

Current report 8-K

Entered into a material agreement, Change to shareholders' rights

Apr 29

Proxy statement DEF 14A Meeting May 17, 2024

Proxy statement

Apr 29

Annual report to holders ARS

Annual report to holders

Apr 17

Current report 8-K

Entered into a material agreement, Change to shareholders' rights, Charter or bylaw amendment, or fiscal year change, Other events

Apr 3

Current report 8-K Events of Apr 2

Other events

Mar 7

Current report 8-K Events of Mar 6

Other events

Feb 21

Current report 8-K Events of Feb 16

Director or officer change, or executive pay

Feb 16

Current report 8-K/A Events of Dec 7

Current report

Feb 8

Annual report 10-K FY2023, ended Dec 31

Annual report for FY2023

Revenue $192.64M ▼ 24.3% Net income $2.51M ▼ 60.0% Diluted EPS $0.04 ▼ 63.6%

Feb 7

Earnings call

Q4 2023 earnings call

Feb 7

Current report 8-K

Financial results

Feb 5

Current report 8-K

Other events

Dec 15

Current report 8-K Events of Dec 13

Charter or bylaw amendment, or fiscal year change

Dec 7

Current report 8-K

Entered into a material agreement, Completed an acquisition or sale of assets, Other events

Nov 9

Quarterly report 10-Q FY2023 Q3, ended Sep 30

Quarterly report for FY2023 Q3

Revenue $38.82M ▼ 40.6% Net income $137K ▼ 95.8% Diluted EPS $0.00

Nov 8

Earnings call

Q3 2023 earnings call

Nov 8

Current report 8-K

Financial results

Aug 21

Current report 8-K Events of Aug 16

Other events

Jul 28

Quarterly report 10-Q FY2023 Q2, ended Jun 30

Quarterly report for FY2023 Q2

Revenue $46.06M ▼ 28.5% Net income $1.52M ▼ 40.9% Diluted EPS $0.03 ▼ 40.0%

Jul 27

Earnings call

Q2 2023 earnings call

Jul 27

Current report 8-K

Financial results

Jun 8

Current report 8-K

Shareholder vote results

May 11

Current report 8-K Events of May 10

Other events

May 3

Earnings call

Q1 2023 earnings call

May 3

Current report 8-K

Financial results

May 3

Quarterly report 10-Q FY2023 Q1, ended Mar 31

Quarterly report for FY2023 Q1

Revenue $62.5M ▲ 3.8% Net income $3.25M Diluted EPS $0.06

May 3

Registration statement S-3/A

Registration statement

Apr 24

Proxy statement DEF 14A

Proxy statement

Apr 24

Annual report to holders ARS

Annual report to holders